rilapladib

inhibits lipoprotein-associated phospholipase A2

Also Known As:

2-(2-((2,3-difluorobenzyl)sulfanyl)-4-oxoquinolin-1(4H)-yl)-N-(1-(2-methoxyethyl)piperidin-4-yl)-N-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)acetamide; SB-659032

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Acetamides: 21
    - rilapladib: 3
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - Acetamides: 21
        rilapladib: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - rilapladib: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        rilapladib: 3

Experts

1.	Alexpandi, Rajaiah: 1 article (01/2020)
2.	De Mesquita, Joelma Freire: 1 article (01/2020)
3.	Pandian, Shunmugiah Karutha: 1 article (01/2020)
4.	Ravi, Arumugam Veera: 1 article (01/2020)
5.	Barnett, Carly: 1 article (09/2015)
6.	De'Ath, Jeni: 1 article (09/2015)
7.	Lavrov, Arseniy: 1 article (09/2015)
8.	Lockhart, Andrew: 1 article (09/2015)
9.	Maher-Edwards, Gareth: 1 article (09/2015)
10.	Brannan, Sarah P: 1 article (01/2014)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 09/01/2015 - "A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease." 09/01/2015 - "The lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer's disease (AD). "
2.	Cerebrovascular Disorders (Cerebrovascular Occlusion) 09/01/2015 - "One hundred twenty-four subjects with possible mild AD and with neuroimaging evidence of cerebrovascular disease were randomized to placebo or 250-mg rilapladib once daily, for 24 weeks, in addition to stable background acetylcholinesterase inhibitor and/or memantine. "
3.	Arteritis 01/07/2014 - "Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging."
4.	COVID-19 01/01/2020 - "In conclusion, owing to their ability to target functional macromolecules of SARS-CoV-2, along with positive ADMET properties, quinoline,1,2,3,4-tetrahydro-1-[(2-phenylcyclopropyl)sulfonyl]-trans-(8CI), saquinavir, elvitegravir, oxolinic acid, and rilapladib are suggested for the treatment of COVID-19."

Related Drugs and Biologics

1.	Biomarkers (Surrogate Marker)
2.	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)
3.	Saquinavir (Invirase)
4.	Oxolinic Acid
5.	Memantine (Namenda)
6.	Cholinesterase Inhibitors (Anticholinesterases)
7.	elvitegravir
8.	quinoline